Trial Profile
A Phase 2 Study of the Safety, Tolerability, and Efficacy of Parsaclisib in Combination With Ruxolitinib in Subjects With Myelofibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary) ; Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 13 Dec 2022 Final Results From a Phase 2 Study assessing efficacy and safety results from the completed study presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2022 According to an Incyte media release, data from this study were presented at the 64th American Society of Hematology (ASH) Annual Meeting.
- 10 Dec 2022 Results published in the Media Release